Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 07, 2018 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2018 First-Quarter Financial Results, Host Conference Call on February 14

MIAMI, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU) today announced that on February 14, 2018, the company will report financial results for its fiscal 2018 first quarter ended December...
February 06, 2018 08:30 ET | Source: Veru Inc.

Veru Announces Presentation of Data Demonstrating Efficacy of VERU-111 in a Taxane Resistant Human Prostate Cancer Model at the 2018 Genitourinary Cancers Symposium

MIAMI, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU) today announced data from a pre-clinical study of VERU-111, a novel oral alpha and beta tubulin inhibitor, showing potent activity...
January 02, 2018 07:00 ET | Source: Veru Inc.

Veru Reports Fiscal 2017 Fourth-Quarter, Full-Year Financial Results

-- Fiscal 2017 Marked by Actions to Advance Drug Pipeline; First New Drug Application (NDA) on Track for Submission in First Half of 2018; Three Additional NDAs Expected to be Filed: Two in 2019 and...
December 11, 2017 08:30 ET | Source: Veru Inc.

Veru Acquires Novel Proprietary Formulation for Overactive Bladder

--Addresses Large Population of Men and Women Who Have Overactive Bladders And Difficulty Swallowing Tablets----FDA Meeting Confirms Single Bioequivalence Study Path to Approval----Expands Offering of...
November 13, 2017 08:30 ET | Source: Veru Inc.

Veru Announces Tamsulosin DRS Bioequivalence Clinical Trial Results

MIAMI, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU) today announced the results of the bioequivalence (BE) clinical trial of the company’s proprietary Tamsulosin Delayed Release Sachet...
October 03, 2017 08:30 ET | Source: Veru Inc.

Veru Inc. Announces Agreement with Timm Medical Technologies, LLC to Distribute and to Promote PREBOOST

MIAMI, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Veru Inc. (Nasdaq:VERU), a biopharmaceutical company focused on urology and oncology, today announced it has signed a United States distribution and...
September 26, 2017 08:36 ET | Source: Veru Inc.

Veru Inc. Announces Initiation of Telemedicine Capability to Expand Access to Prescriptions for FC2 Female Condom

MIAMI, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Veru Inc. (Nasdaq:VERU), (formerly, Nasdaq:FHCO) (”Veru” or the “company”), a biopharmaceutical company focused on urology and oncology, today announced the...
September 20, 2017 08:30 ET | Source: Veru Inc.

Veru Inc. to Present at Two Financial Conferences in September

MIAMI, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Veru Inc. (Nasdaq:VERU), (formerly, Nasdaq:FHCO), a biopharmaceutical company focused on urology and oncology, today announces that it will participate in...
September 05, 2017 08:30 ET | Source: Veru Inc.

Veru Inc. to Participate in Upcoming Financial Conferences

MIAMI, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Veru Inc. (Nasdaq:VERU) (formerly, Nasdaq:FHCO) (”Veru” or the “company”), a biopharmaceutical company focused on urology and oncology, today announces that...
August 10, 2017 08:30 ET | Source: Veru Inc.

Veru Inc. Announces Change in Nasdaq Ticker Symbol to VERU

MIAMI, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Veru Inc. (Nasdaq:VERU) (formerly, Nasdaq:FHCO) (”Veru” or the “company”), formerly known as Veru Healthcare/The Female Health Company, a biopharmaceutical...